Inventor

COULIE PIERRE

BE49 patents

⚠️ This page may combine multiple inventors who share the name “COULIE PIERRE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

COULIE PIERRE

LUDWIG INST CANCER RES

Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.

Method for screening for possible presence of cancer

Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Isolated nucleic acid molecule which codes for a tumor rejection antigen precursor which is processed to an antigen presented by HLA-B44, and uses thereof

Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors

Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals

Isolated, tyrosinase derived peptides and uses thereof

Uses of substantially pure interleukin-9 receptor

Substantially pure interleukin-9 receptor and uses thereof

Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof

Endogenous retrovirus tumor associated nucleic acids and antigens

Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Isolated nucleic acid molecules which encode tumor rejection antigens found in dage

Methods for treating subject with DAGE derived peptides

Isolated cytolytic T cell line specific to complexes of HLA-B44 molecules and specific nonapeptides

Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individuals

MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof

Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof

Isolated protein processed to peptides which form complexes with HLA molecules

Isolated tumor rejection antigens derived from DAGE tumor rejection antigen precusor

Isolated peptides which bind to HLA-B44 Molecules

Method for diagnosing a disorder characterized by expression of a BAGE tumor rejection antigen precursor

Isolated tyrosinase derived peptides and uses thereof

Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens

Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof

Methods for determining complexes of tumor rejection antigens and HLA-Cw*160/molecules

MAGE-C2 antigenic peptides and uses thereof

Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof

Cytolytic T cell lines which bind to complexes of tumor rejection antigens and HLA-B44 molecules

Immunogenic compositions of tumor rejection antigen precursor MAGE-10 and an adjuvant

Isolated tumor rejection antigen precursor MAGE-10 and compositions containing it

Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules

Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individuals

Isolated peptide defined by SEQ ID NO: 17 and uses thereof

Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof

Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecule HLA-Cw*1601 and uses thereof

Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of hla-cw 1601/mage-1 derived peptides, and methods for treating said individuals

MAGE-10 encoding CDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof

LUDWIG INST FOR CANCER RES LTD

Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody

Anti-GARP protein

Antibody against a complex between human GARP and latent TGF-β

ARGENX BVBA

Nucleic acids encoding GARP-TGF-beta 1 antibodies

GARP-TGF-β 1 IGG antibodies

GARP-TGF-beta 1 antibodies

UNIV CATHOLIQUE LOUVAIN

Method of screening for anti-GARP antibodies

MA WENBIN

MAGE-C2 antigenic peptides and uses thereof